deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT01837862

A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas

Sponsor: Janssen Pharmaceuticals

Conditions Anaplastic Astrocytoma Brainstem Glioma DIPG Diffuse Intrinsic Pontine Glioma Glioblastoma Multiforme Glioma, Astrocytic Gliosarcoma Low-grade Glioma Optic Nerve Glioma Pilocytic Astrocytoma Pilomyxoid Astrocytoma Pleomorphic Xanthoastrocytoma
Interventions Bevacizumab Carboplatin Irinotecan Mebendazole Temozolomide Vincristine
Updated 12 times since 2017 Last updated: Jul 3, 2024 Started: Oct 22, 2013 Primary completion: Apr 30, 2024 Completion: Apr 30, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01837862, this PHASE1/PHASE2 trial focuses on Anaplastic Astrocytoma and Brainstem Glioma and remains completed. Sponsored by Janssen Pharmaceuticals, it has been updated 12 times since 2013, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotRecruiting~Feb 2017 – ~Mar 2018 · 13 months · monthly snapshotRecruiting~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshotRecruiting~Jun 2018 – ~Apr 2019 · 10 months · monthly snapshotRecruiting~Apr 2019 – ~Jan 2021 · 21 months · monthly snapshotRecruiting~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshotRecruiting~Apr 2021 – ~May 2022 · 13 months · monthly snapshotRecruiting~May 2022 – ~May 2023 · 12 months · monthly snapshotRecruiting~May 2023 – ~Jul 2024 · 14 months · monthly snapshotRecruiting~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshotRecruiting~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshotCompleted~Sep 2024 – present · 20 months · monthly snapshotCompleted

Change History

12 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Aug 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Status: Recruiting → Completed

  3. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. May 2023 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

  5. May 2022 — May 2023 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 7 earlier versions

  1. Apr 2021 — May 2022 [monthly]

    Recruiting PHASE1_PHASE2

  2. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE1_PHASE2

  3. Apr 2019 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  4. Jun 2018 — Apr 2019 [monthly]

    Recruiting PHASE1_PHASE2

  5. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  6. Feb 2017 — Mar 2018 [monthly]

    Recruiting PHASE1_PHASE2

  7. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Oct 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Janssen Pharmaceuticals
  • Julie Krystal
Data source: Northwell Health

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations